论文部分内容阅读
罗氏制药有限公司在上海召开的新闻发布会上宣布:由该公司研制的主治乳腺癌及直肠癌的第一个新型氟嘧啶类药物希罗达在中国市场正式上市。 1999年11月希罗达开始在中国进行注册临床研究试验,由北京、上海、广州、武汉的5家国家抗肿瘤药物临床实验研究中心进行临床试验,有71例蒽环类、紫杉醇治疗无效的晚期乳腺癌患者接受试验,总有效率达32.4％,疗效与国外相似,不良反应轻微,对于脏器转移灶也有肯定疗效。 卫生部新药评审委员会肿瘤组组长、我国著名肿瘤专家、希罗达在中国研究的主要研究者管忠震教授
At a press conference in Shanghai, Roche Pharmaceuticals announced that Xeloda, the first new fluoropyrimidine-based drug for breast cancer and rectal cancer developed by the company, was officially launched in the Chinese market. In November 1999, Xeloda began clinical trials in China. Five clinical trial centers of anticancer drugs in Beijing, Shanghai, Guangzhou and Wuhan conducted clinical trials. There were 71 anthracyclines and paclitaxel ineffective Patients with advanced breast cancer were tested, the total effective rate of 32.4%, similar efficacy and foreign, mild adverse reactions, organ metastases also have a positive effect. Ministry of Health Drug Review Committee of tumor team leader, our famous oncologist, Xeloda main researcher in China, Professor Guan Zhong Zhen